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Abstract
Evidence from mouse chronic viral infection models suggests that CD8+ T cell subsets 
characterized by distinct expression levels of the receptor PD-1 diverge in their state of exhaustion 
and potential for reinvigoration by PD-1 blockade. However, it remains unknown whether T cells 
in human cancer adopt a similar spectrum of exhausted states based on PD-1 expression levels. We 
compared transcriptional, metabolic, and functional signatures of intratumoral CD8+ T 
lymphocyte populations with high (PD-1T), intermediate (PD-1N) and no PD-1 expression (PD-1-) 
from non-small cell lung cancer patients. We observed that, PD-1T T cells show a markedly 
different transcriptional and metabolic profile as compared to PD-1N and PD-1- lymphocytes, as 
well as an intrinsically high capacity for tumor recognition. Furthermore, while PD-1T 
lymphocytes are impaired in classical effector cytokine production, they produce CXCL13 that 
mediates immune cell recruitment to tertiary lymphoid structures. Strikingly, the presence of 
PD-1T cells was strongly predictive for both response and survival in a small cohort of non-small 
cell lung cancer patients treated with PD-1 blockade. The characterization of a distinct state of 
tumor-reactive, PD-1 bright lymphocytes in human cancer, which only partially resembles that 
seen in chronic infection, provides novel potential avenues for therapeutic intervention.
Keywords
T cell exhaustion; NSCLC; chemokine; CXCL13; IL-10; immune checkpoint blockade
Introduction
Tumors with substantial amounts of DNA damage commonly induce tumor-reactive CD8+ T 
cell responses in both mouse models and cancer patients1,2. Successful elimination of 
cancer cells by these tumor-infiltrating lymphocytes (TILs) is however hampered by a broad 
set of immunosuppressive mechanisms that are active in the tumor microenvironment 
(TME)3–5, and this includes the upregulation of immune checkpoint proteins such as PD-1, 
CTLA-4, Tim-3 and Lag-3 on TILs6. T cells that express these checkpoint molecules are 
thought to be characterized by a state of dysfunction, termed T cell exhaustion, that was 
originally discovered in chronic murine lymphocytic choriomeningitis virus (LCMV) 
infection7–9, but for which evidence has also been obtained in human infections and 
cancer6,10–16. The successful reinvigoration of T cell function by blockade of PD-1 or its 
ligand PD-L1 highlights the importance of this pathway in T cell exhaustion10.
Notably, in chronic LCMV infection, two subsets of exhausted PD-1+ T cells with distinct 
responses to PD-1/PD-L1 blockade have been identified. Specifically, whereas mouse T 
cells with high expression of the transcription factor T-bet and intermediate expression of 
PD-1 (T-bethi PD-1int) can be reinvigorated by in vivo blockade with anti-PD-L1, terminally 
differentiated T cells with high Eomesodermin (Eomes) and high PD-1 expression (Eomeshi 
PD-1hi) do not respond17,18. Similarly, a high percentage of PD-1hi cells within CD8+ TILs 
has been shown to correlate with a limited response to PD-1 blockade upon polyclonal 
stimulation of T cells in human lung cancer samples14. However, the relationship between 
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PD-1int and PD-1hi TILs in human cancer has not been established, and their resemblance to 
their counterparts in murine chronic infection has been unclear. To address these issues, we 
analyzed the properties of three populations of intratumoral CD8+ TILs with defined levels 
of PD-1 expression in patients with non-small cell lung cancer (NSCLC): CD8+ TILs 
without detectable PD-1 expression (PD-1-), CD8+ TILs with a PD-1 expression level 
similar to that on healthy donor PBMCs (PD-1N), and CD8+ TILs with levels of PD-1 that 
exceed those commonly observed on healthy donor PBMCs (PD-1T). Using this approach, 
we evaluated (i) whether PD-1T and PD-1N characterize different cell states in human 
cancer, (ii) whether PD-1T T cells in human cancer display the same defects as have been 
observed in murine chronic infection, and (iii) whether tumor reactivity is equally contained 
in the different PD-1 positive TIL subsets in human tumor lesions. Our data demonstrate that 
tumor reactivity is to a large extent restricted to the PD-1T subset, and that these cells 
display a functional state that is distinct from that of both PD-1N T cells in cancer and of 
PD-1hi T cells in chronic infection, and characterized by high levels of CXCL13 production. 
Furthermore, the presence of PD-1T TILs was highly predictive for response and survival 
upon anti-PD-1 treatment in NSCLC.
Results
PD-1 expression level identifies TIL subsets with distinct phenotype, function and tumor 
reactivity
To first understand whether the expression level of PD-1 can be used to identify tumor-
infiltrating CD8+ T cells that differ in the expression of other inhibitory receptors18–20, we 
determined the expression of Tim-3, Lag-3, TIGIT, 2B4 (CD244), and BTLA in nine subsets 
of CD8+ TILs from 24 NSCLC specimens that were subdivided according to their PD-1 
mean fluorescence intensity (MFI) (Fig. 1a and Supplementary Fig. 1a). For all inhibitory 
receptors, the percentage of expressing cells, but also the level of inhibitory receptor 
expression, was clearly correlated with PD-1 expression levels (Fig. 1b and Supplementary 
Fig. 1b-d). Whereas TIGIT and 2B4 were also expressed in T cells with intermediate and 
low PD-1 levels, Tim-3 and Lag-3 were almost exclusively found on lymphocytes with high 
levels of PD-1 expression. To establish a more objective subdivision of PD-1+ populations 
that can be applied across studies, we compared the PD-1 expression levels on NSCLC TILs 
with those of peripheral blood T cells from healthy donors. In peripheral blood of healthy 
donors (n=6), a clear population of PD-1-negative T cells and T cells with an intermediate 
level of PD-1 could be detected, with very few T cells displaying higher levels of PD-1 
(average of 0.4%). In contrast, in TILs, sometimes sizable populations of T cells with bright 
PD-1 expression were detected (fraction of PD-1 bright within CD8+ TILs: 29.1±17.6%, 
n=24) (Fig. 1c and Supplementary Fig. 1e). Reflecting the definition of these cells on the 
basis of their tumor-associated level of PD-1 expression, we here refer to these cells as 
‘PD-1T’ (‘tumor-associated’) TILs. Remaining TILs were divided into those with a PD-1 
level equal to that seen in peripheral blood (‘PD-1Normal, PD-1N’ TILs) and TILs with no 
detectable PD-1 expression (‘PD-1-’ TIL, Fig. 1c).
As effector functions are gradually lost during progressive T cell exhaustion8, with a recent 
study reporting an inverse correlation between T cell function and PD-1 expression levels21, 
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we first assessed cytokine secretion by sorted PD-1T, PD-1N and PD-1- TILs from three 
NSCLC samples (Supplementary Fig. 1f,g). Sorted cells were rested overnight and then 
stimulated using anti-CD3/anti-CD28 antibodies. While the PD-1N and PD-1- subsets 
produced all effector cytokines, PD-1T TILs failed to produce substantial levels of IL-2, 
TNF-α and IFN-γ (Fig. 1d). Analysis of CD28 levels ruled out differential CD28 
expression as a cause for this difference in responsiveness (Supplementary Fig. 1h).
Collectively, the above data were consistent with a model in which increasing exhaustion 
leads PD-1N cells to convert to PD-1T cells. To test this, we assessed two additional 
properties of these intratumoral T cell subsets. First, we assessed whether, as in chronic viral 
infection, the PD-1T state was associated with the expression of Eomes and not T-bet. 
Second, we assessed whether there was a sharing in the TCR repertoire of the intratumoral 
PD-1T subset with that of the other subsets. Analysis of Eomes and T-bet expression in cells 
with different levels of PD-1 expression showed that, in contrast to what is observed during 
chronic LCMV infection18, expression of both transcription factors in human TILs is not 
correlated with the level of PD-1 (Supplementary Fig. 1i). Furthermore, analysis of T cell 
receptor (TCR) beta sequences extracted from RNA expression data22 revealed that the 
PD-1T subset was characterized by a significantly higher clonality, with the top 30 clones 
contributing close to 90% of the entire TCR repertoire (Fig. 1e). While some sharing of the 
top 30 clones with PD-1N and PD-1- TILs could be observed, the abundance of these clones 
was significantly lower in the other two subsets (Fig. 1f, Supplementary Table 1).
The observed clonal expansion of one or a few dominant clones within the PD-1T cell 
population suggested that the PD-1T phenotype may be driven by TCR triggering 
(Supplementary Fig. 2a). Consistent with this hypothesis, we observed a high expression of 
the co-stimulatory receptor CD137 (4-1BB) on cells with high PD-1 levels (Fig. 1g), 
potentially reflecting recent antigen encounter23. Recent data in melanoma indicate that 
tumor-reactive T cells are enriched in PD-1+ and PD-1 high populations relative to the bulk 
T cell population13,24–26, although from this work it is unclear whether tumor recognition 
potential differs between subsets with high and intermediate expression of PD-1. To test 
whether the PD-1T and PD-1N TIL subsets may differ in their capacity for tumor 
recognition, we first expanded the PD-1 subsets from eight tumors under the conditions used 
to generate TIL products for adoptive transfer24 (Supplementary Fig. 2b, note that the 
PD-1T subset is dysfunctional directly ex vivo). During in vitro expansion, PD-1 expression 
on the PD-1N and in particular PD-1T TILs was reduced, and PD-1T TILs regained their 
capacity to exert effector functions (Fig. 1h). Strikingly, subsequent co-culture of expanded 
PD-1T, PD-1N and PD-1- TIL populations with autologous tumor digests revealed that, for 
seven out of eight patients, tumor reactivity was enriched in (n=1) or almost fully restricted 
to (n=6) the PD-1T TIL derived cell populations. In one patient, tumor recognition was 
observed in both PD-1T and PD-1N TILs (Fig. 1i and Supplementary Fig. 2b+c).
The transcriptional profile of PD-1T TILs is distinct from both human PD-1N TILs and PD-1hi 
T cells in chronic viral infection
Having established that PD-1T T cells in human lung cancer are enriched for tumor 
reactivity but display phenotypic differences to previously described dysfunctional states, we 
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further characterized this cell population by analysis of RNAseq data from 11 human lung 
cancers (Supplementary Fig. 1f, sample QC in Supplementary Fig. 1g). Principal component 
analysis of the gene expression profiles of sorted PD-1T, PD-1N and PD-1- TILs, and 
peripheral blood CCR7- CD45RA- effector memory (TEM) CD8+ T cells from healthy 
donors, showed that – as expected – all three TIL populations cluster away from peripheral 
blood TEM cells (Fig. 2a). Strikingly, PD-1N and PD-1- TILs showed almost overlapping 
gene expression profiles, whereas PD-1T TILs displayed a gene signature that was markedly 
distinct from both other subsets. Specifically, a total of 577 genes (including PDCD1 itself, 
Supplementary Fig. 3a). were significantly upregulated or downregulated (log2 fold change 
>1, adjusted p-value <0.01) between PD-1T and PD-1N TILs. In contrast, only eight genes 
showed significantly different expression between PD-1N and PD-1- TILs (Fig. 2b, 
Supplementary Table 2). Hierarchical clustering analysis revealed eight clusters of genes 
that displayed distinct expression profiles between PD-1T and PD-1N TILs (Fig. 2c, 
Supplementary Table 2). Of note, gene expression profiles were highly similar within the 
PD-1T samples from different patients, in spite of variation in histologic subtype (five 
adenocarcinomas, four squamous cell carcinomas and two sarcomatoid carcinomas, 
Supplementary Fig. 3b). We then used pathway-enrichment analysis to identify biological 
processes that were substantially changed in PD-1T TILs (Fig. 2d). In contrast to exhausted 
T cells in chronic infection, which lose their proliferative capacity during exhaustion8, genes 
involved in cell cycle regulation and proliferation were among the most upregulated genes in 
PD-1T TILs (Fig. 2e). Sorted PD-1T TILs also showed a significantly higher expression of 
the proliferation marker Ki67 (MKI67) at the protein level, which was maintained after 48 
hrs of culture without further stimulation (Fig. 2f). Cell cycle analysis revealed a 
significantly higher percentage of cells in S- and G2/M-phase within the PD-1T subset 
(PD-1T: 9.1±4.6%; PD-1N: 1.75±1.1%; PD-1-: 0.5±0.4%, PD-1T KI67+: 23.8±8%), 
confirming that these cells are able to progress through the cell cycle. Further processes that 
were highly altered in PD-1T TILs related to cell migration and metabolism, indicating that 
the changes in PD-1T TILs comprise a broad spectrum of core cellular processes.
We observed increased mRNA levels for the inhibitory receptors Tim-3, Lag-3, and 
CTLA-4, coinciding with their increased protein levels on PD-1T T cells (Fig. 1). PD-1T 
TILs also showed high expression of a wide array of other receptors with known inhibitory 
function including CD200, CD109, CD39 (ENTPD1), as well as glucocorticoid-induced 
TNFR-related protein (GITR, TNFRSF18), and displayed reduced expression of activating 
receptors such as CD26 (DPP4) at both the RNA and protein level (Fig. 3a,b). In addition, 
genes encoding receptors with potential inhibitory function that have recently been identified 
by single cell sequencing of exhausted CD8+ TILs in hepatocellular carcinoma27, including 
LAYN, SNAP47 and PHLDA1, were highly expressed by PD-1T T cells (Fig. 3c). High 
clonal expansion of T cells is generally associated with expression of the senescence marker 
KLRG128 and loss of the co-stimulatory receptor CD27. However, PD-1T TILs showed 
lower KLRG1 and higher CD27 expression than their PD-1N and PD-1- counterparts (Fig. 
3d).
To further test to what extent PD-1T T cells in human cancer are distinct from the exhausted 
state that occurs in chronic viral infection, we performed gene set enrichment analysis using 
established exhaustion signatures from T cells in chronic infection or cancer. Initially, we 
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compared the exhaustion signature derived from virus-specific exhausted T cells in chronic 
LCMV infection29 with both PD-1T and PD-1N TILs, demonstrating a similar enrichment 
of this signature in both subsets (Fig. 3e,f). We also compared human PD-1T and PD-1N 
TILs with respect to the gene signature that is shared by T cells in early- and late-stage 
murine tumors30. Also in this case, the gene signature was equally enriched in both PD-1T 
and PD-1N subsets (Fig. 3e,g). As these gene sets may describe different subsets of 
exhausted T cells, we also included gene sets from human or murine cancer6,27,31,32, 
human chronic viral infections33,34 or murine LCMV infection35, that were derived from 
either PD-1hi subsets or from T cells expressing surface markers that are also upregulated in 
PD-1T TILs (e.g. Tim-3), and thus might better reflect the latter subset. Comparison of these 
gene signatures revealed that PD-1T T cells were most similar to exhausted PD-1 bright T 
cell populations in human cancers that were identified by single cell sequencing 
(Supplementary Fig. 3c). In contrast, the lowest similarity was observed between PD-1T 
cells and exhausted Tim-3+PD-1+ T cells in murine cancer (Supplementary Fig. 3d). 
Interestingly, while an intermediate overlap with signatures from PD-1hi T cells in chronic 
infections was observed, shared genes mostly related to processes involved in cell division 
and proliferation. In contrast, the enriched genes from exhausted cells in human cancer were 
associated with T cell activation and immune response (Supplementary Fig. 3e).
PD-1T TILs display profound alterations in metabolism
Recent data from murine tumor models have shown that T cells undergo profound metabolic 
changes upon entering the TME which lead to metabolic insufficiency36–38. While 
activated T cells utilize anaerobic glycolysis to meet the increasing demands necessary for 
proliferation and cytokine production39,40, they also become increasingly dependent on 
mitochondrial fatty acid oxidation for memory formation41. However, glucose deprivation 
in the TME and loss of mitochondrial function have been found to impair the antitumor 
activity of T cells36–38. Thus, we next investigated whether PD-1T TILs display alterations 
in glucose, lipid and mitochondrial metabolism using metabolic dyes. Strikingly, PD-1T 
TILs showed a significantly increased glucose uptake (detected by 2-NBDG) compared to 
both other subsets (Fig. 4a,b). A recent study observed a similar increase in exhausted HBV-
specific T cells42. Notably, while T cells need increased glycolytic activity to execute 
effector functions, prolonged glycolysis has been found to impair antitumor function of 
CD8+ T cells, thereby contributing to their dysfunction43. Similar to the upregulation of 
glycolysis, lipid uptake (Bodipy 500) and content (Bodipy 493) as well as expression of the 
scavenger receptor CD36, which mediates uptake of fatty acids, were clearly increased in 
PD-1T TILs (Fig. 4a+c). In order to benchmark the magnitude of these alterations, we used 
the changes in circulating T cells upon anti-CD3/anti-CD28 stimulation as a reference, 
demonstrating that the changes between PD-1T and both other subsets were of a similar 
magnitude as seen upon peripheral blood T cell activation (Supplementary Fig. 4a). Notably, 
despite having a slightly larger mitochondrial mass as indicated by mitotracker green (MTG) 
staining (Fig. 4a,d), PD-1T TILs showed a significantly reduced mitochondrial membrane 
potential (mitotracker red, MTR) (ΔΨm), which was retained even after normalization of 
ΔΨm to the mitochondrial mass (MTR/MTG ratio), indicating mitochondrial dysfunction 
(Fig. 4a,d). Transmission electron microscopy confirmed that, while PD-1T TILs show an 
increase in mitochondria numbers, these mitochondria display profound morphological 
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changes, with reduced cristae numbers and with a trend towards reduced cristae length (Fig. 
4e). PD-1T TILs not only normalized their PD-1 expression and function after in vitro 
expansion but also their metabolism, suggesting that the metabolic dysfunction of this T cell 
pool can also be reverted outside of the TME (Supplementary Fig. 4b).
PD-1T TILs possess an inherited state of dysfunction
As shown above (Fig. 1h), in vitro expansion in the presence of IL-2 can restore cytokine 
production and reduce PD-1 expression of PD-1T TILs. Nevertheless, expanded PD-1T–
derived TILs still expressed higher levels of the inhibitory receptors Tim-3 and Lag-3 
compared to the other two subsets (Fig. 5a), potentially suggesting an underlying state of 
dysfunction. Transcriptome and functional analyses revealed changes in interleukin-10 
(IL-10) and pSTAT3 signaling between PD-1T TILs and the PD-1N/PD-1- subsets 
(Supplementary Fig. 5a,b). In addition, we found IL-10 to be widely expressed by 
monocytes and tumor cells in NSCLC (but not by PD-1T cells themselves), and the number 
of IL-10 producing cells correlated with the number of PD-1T TILs (Fig. 5b and 
Supplementary Fig. 5c). Strikingly, when we exposed IL-2 expanded TIL subsets to IL-10, 
PD-1T-derived TILs rapidly re-expressed high levels of PD-1, whereas no substantial effect 
on PD-1N- and PD-1--derived TIL subsets was observed (Fig. 5c). Similarly, expansion in 
IL-10 reduced IFN-γ production, with the most severe impairment in PD-1T–derived TILs 
(Fig. 1h, Fig. 5d). The differential effect of IL-10 on PD-1T TILs was not due to increased 
IL-10R signaling, as shown by comparable downregulation of IL-10R and increase in 
perforin expression, a known downstream effect of IL-10R signaling44, in all subsets (Fig. 
5e). These findings suggest that PD-1T TILs are particularly susceptible to 
immunosuppressive factors such as IL-10 due to an inherited state of dysfunction, which 
may impede efforts to reinvigorate these cells.
PD-1T TILs acquire a novel effector function and predict response to PD-1 blockade
While PD-1T TILs were highly dysfunctional in terms of classical CD8+ T cell effector 
cytokine secretion, transcriptome analysis revealed that the effector chemokine CXCL13 
was among the most upregulated genes within this subset (Supplementary Table 2 and Fig. 
3a). PD-1T TILs not only expressed, but also constitutively secreted CXCL13 (Fig. 6a and 
Supplementary Fig. 6a). CXCL13 exclusively binds to the chemokine receptor CXCR5, 
which is normally expressed on B cells and CD4+ follicular helper T (Tfh) cells, but has 
recently been shown to also mark a subset of exhausted virus-specific CD8+ T cells in 
lymphoid tissues that responds to PD-1 blockade45,46. The main function of CXCL13 is to 
control the recruitment and organization of B cells within lymphoid follicles47. Thus, 
CXCL13 secretion by PD-1T TILs might serve to attract other immune cell subsets to the 
TME. To address this, we investigated the ability of sorted peripheral blood CXCR5+ 
immune cell subsets including CD8+, CD4+ T cells and B cells from NSCLC patients to 
migrate in response to CXCL13 in vitro (Fig. 6b). We found that all subsets showed 
chemotaxis to CXCL13 compared to CXCR5- CD3+ T cells, with migration of CXCR5+ 
CD4+ T cells being the most pronounced. We hypothesized that if PD-1T TILs mediate 
recruitment of Tfh and B cells, these three subsets would co-localize within the TME. We 
therefore identified PD-1T TILs in NSCLC samples by CD8/PD-1 double staining and 
digital image analysis using an algorithm to detect CD8+ TILs with strong PD-1 expression 
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(Fig. 6c-e, see also below). Strikingly, PD-1T TILs were predominantly localized in intra- 
and peritumoral tertiary lymphoid structures (TLS) in close vicinity to Tfh, marked by CD4 
and Bcl6, and B cell infiltrates (Fig. 6d,f). In most tumors, PD-1T TILs surrounded the 
central B cell area and were found at the tumor-host interface (Fig. 6e), suggesting that 
PD-1T TILs may play an active role in the recruitment of immune subsets to the TME.
Based on the observation that PD-1T TILs are the most prominent tumor-reactive T cell pool 
in NSCLC (Fig. 1i), we investigated whether these cells might also be predictive for 
response to PD-1-targeting therapies. To this end, we used parallel analysis of two parts of a 
set of tumor samples to establish an algorithm-based quantitative PD-1 
immunohistochemistry (IHC) assay for paraffin-embedded tissue by comparing with flow 
cytometric PD-1T quantification of the same sample. The algorithm generated in this manner 
was subsequently validated by independent analysis of a second and third set of slides from 
the same tumor samples at two different institutes (see Methods section, Supplementary Fig. 
6b,c). Having validated this strategy for quantitative analysis of PD-1T cell levels, we 
applied this method to evaluate the presence of PD-1T cells in pretreatment biopsies of 21 
stage IV NSCLC patients undergoing anti-PD-1 therapy (Supplementary Fig. 6d). Strikingly, 
presence of PD-1T TILs very strongly predicted response to therapy (Fig. 6g), and also 
correlated with increased overall survival (HR 0.16 (95% CI 0.05-0.52), p<0.05) and durable 
responses (Fig. 6h,i) in this cohort. In contrast, the predictive value of PD-1N TILs was 
lower (Supplementary Fig. 6e). These findings indicate that the presence of PD-1T TILs may 
represent a novel biomarker for response to agents that target the PD-1/PD-L1 axis.
Discussion
Cancer immunotherapies that reactivate tumor-specific T cells through blockade of the 
PD-1/PD-L1 axis have emerged as a promising treatment option for many cancers48. 
However, prior studies indicate that not all PD-1+ cells might respond equally to anti-PD-1 
treatment14,17. Here we describe the properties of T cells with different PD-1 expression 
levels in NSCLC and their potential relationship with immune-mediated tumor control. Our 
data show that PD-1T TILs in NSCLC are a highly exhausted T cell subset that displays 
profound molecular, metabolic and functional differences relative to PD-1N and PD-1- TILs, 
and that also contains the bulk of the tumor recognition potential of intratumoral CD8+ 
lymphocytes.
T cell exhaustion was originally described in murine chronic viral infections, where 
persistent antigenic stimulation may be the main driver of this dysfunctional state8. In 
cancer, the TME is likely to provide additional immunosuppressive stimuli that may further 
modulate exhaustion. Supporting this hypothesis, we found that, while PD-1T TILs share 
key characteristics such as overexpression of inhibitory receptors and loss of effector 
cytokine secretion with PD-1hi T cells from chronic infection, they clearly differ in many 
cellular core processes. First, the clear relationship between Eomes and T-bet expression 
with high and intermediate PD-1 expression levels in chronic infections18 is not present in 
the PD-1 subsets in human lung cancer. Second, PD-1T TILs are a highly clonal T cell 
population with a predominance of TCRs that are present at low abundance in PD-1N TILs, 
suggesting an antigen-driven expansion of this subset rather than a gradual progression in 
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exhaustion from PD-1N to PD-1T TILs as observed in chronic LCMV infection18. Third, in 
contrast to the loss of proliferation in exhausted T cells in chronic infection, processes 
involved in cell cycle and cell division were highly upregulated in lung cancer-derived 
PD-1T TILs, potentially reflecting clonal expansion of this subset upon in vivo antigen 
stimulation. Fourth, PD-1T TILs in human lung cancer show profound metabolic alterations, 
with increased glycolysis and defects in mitochondrial metabolism. Competition for glucose 
in the TME due to increased glycolysis of tumor cells has been shown to impair T cell 
functionality in murine tumor models37. Thus, the limitation of metabolic intermediates that 
are necessary for antitumor activity, might further augment dysfunction of PD-1T TILs. 
Fifth, the gene signature of exhausted T cells from chronic viral infections is not enriched in 
PD-1T TILs relative to PD-1N TILs, and the same applies to the exhaustion signature of 
early and late-stage tumors from murine cancer models30, the exhaustion signatures seen in 
T cells from human infections33,34, or the signature of PD-1hi T cells in LCMV 
infection35. Together, these observations provide compelling evidence that PD-1T TILs in 
human lung cancer display a state of dysfunction that is distinct to those states that have 
been previously described.
A striking aspect of this cell state is the constitutive secretion of the chemoattractant 
CXCL13. Three recent studies investigating T cells in human melanoma and hepatocellular 
carcinoma identified CXCL13 as one of the significantly upregulated genes in highly 
exhausted TILs6,27,31, and the current data, as well as data from a recent study in breast 
cancer49, show that this mRNA expression is accompanied by constitutive protein secretion. 
Furthermore, we observed that CXCL13 secreting PD-1T TILs were predominantly present 
in TLS, suggesting a possible involvement of these cells in the formation of TLS.
The observation that tumor reactivity is to a very large extent restricted to the PD-1T TIL 
subset makes quantification of this subset an attractive proxy for the anti-tumor potential of 
the intratumoral T cell pool. In support of this, retrospective analysis of PD-1T TIL 
infiltration in pretreatment biopsies of NSCLC patients undergoing anti-PD-1 therapy 
revealed a clear correlation between the frequency of these cells and both treatment response 
and patient survival. This clear relationship may either reflect the direct tumoricidal capacity 
of these cells following PD-1 blockade, or their ability to recruit other immune cells that 
mediate the anti-tumor immune response. Collectively, our findings describe PD-1T TILs in 
human lung cancer as a highly distinct cellular pool that has not only lost classical CD8+ 
effector functions but has developed a novel functionality and holds the potential to predict 
patient outcome upon PD-1 targeting therapies. Future work should address whether the 
targeting of any of the other of the large number of known or potential inhibitory receptors 
on these cells can further increase their activity, an effort that is of particular interest in view 
of the high intrinsic tumor reactivity of this subset. In parallel, it will be of interest to 
establish how PD-1T TIL are influenced by PD-1 blockade in human cancer samples, and to 
validate PD-1T TILs as a predictive marker for response to cancer immunotherapy in larger 
prospective trials.
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Online Methods
Patient characteristics and tumor sample processing
Fresh tumor samples were collected from individuals with non-small cell lung cancer 
undergoing primary surgical treatment between January 2013 and June 2016 at the 
University Hospital Basel, Switzerland and at the Ortenau Klinikum, Germany. Paraffin-
embedded tumor biopsies were collected from stage IV non-small cell lung cancer patients 
undergoing treatment with nivolumab between April 2015 and June 2017 at the University 
Hospital Basel and the Cantonal Hospital Baselland, Switzerland. Detailed patient 
characteristics are provided in Supplementary Table 3 and 4. The study was approved by the 
local Ethical Review Board (Ethikkommission Nordwestschweiz), performed in compliance 
with all relevant ethical regulations, and all patients consented in writing to the analysis of 
their tumor samples.
Resected solid tumor lesions were immediately processed into single cell suspensions by 
mechanical dissociation and enzymatic digestion using accutase (PAA), collagenase IV 
(Worthington), hyaluronidase (Sigma) and DNAse type IV (Sigma). All samples were 
cryopreserved until further usage.
Antibodies and phenotypic characterization of T cells
Anti-CD19 APC-eFluor780 (SJ25C1), -CD45 PerCP-Cy5.5 (2D1), -CD56 PE (CMSSB), -
CD3 APC-eFluor780 (SK7), -Lag-3 FITC (3DS223H), -TIGIT PE (MBSA43), -2B4 FITC 
(eBioDM244), -CD137 FITC (4B4), -IL-2 PE (MQ1-17H12), -TNF-α APC (MAb11), -
CD26 FITC (2A6), -CXCR5 Biotin (MU5UBEE), -ICOS FITC (ISA-3), -CD38 APC 
(HIT2), -Eomes eFluor660 (WD1928), -T-bet PE (eBio4B10), -pSTAT3 PE (LUVNKLA) 
were purchased from eBioscience. Anti-CD4 BV711 (SK3), -PD-1 PE-Cy7 (EH12.1), -PD-1 
AlexaFluor647 (EH12.1), -BTLA PE (J168-540), -IFN-γ BV421 (4S.B3), -CD27 BV711 
(M-T271), -CD28 PE-Cy7 (CD28.2), -Ki67 BV421 (B56), -CD20 BV711 (2H7), and 
Streptavidin BV711 and Streptavidin BV605 were purchased from BD. Anti-CD8 BV605 
(RPA-T8), -CD8 BV711 (SK1), -CD8 PE-Cy7 (SK1), -CD4 PE (SK3), -CD11b PE 
(ICRF44), -CD11c PE (3.9), -CD14 PerCP-Cy5.5 (HCD14), -CD45 APC-eFluor780 (HI30), 
-Tim-3 BV421 (F38-2E2), -IL10 PE (JES3-9D7), -CD200 BV421 (OX-104), -CD109 PE 
(W7C5), -GITR APC (621), -CD39 FITC (A1), -CD127 BV605 (A019D5), -CCR7 PE 
(G043H7), -CD45RA BV421 (HI100), -CD62L BV421 (DREG-56), -KLRG1 BV421 (2F1/
KLRG1), -CD36 APC (5-271), -CCR6 PE-Cy7 (G034E3), -CCR4 PE-Cy7 (TG6/CCR4), -
CXCR3 PE (G025H7), -HLA ABC APC-Cy7 (W6/32), and Streptavidin PE-Cy7 were 
purchased from Biolegend and anti-CXCL13 APC (53610) from R&D Systems.
For phenotypic characterization of cryopreserved tumor digests, samples were thawed, 
washed, resuspended in 50 μl PBS and blocked with Fc receptor blocking agent 
(eBioscience) for 20 min at 4°C. Cells were stained with live/dead Zombie UV (Invitrogen). 
Cells were washed, resuspended in 50 μl of staining buffer (PBS, 2mM EDTA, 0.1% NaN3, 
2% fetal calf serum) containing antibodies for surface staining and incubated for 20min at 
4°C. Corresponding isotype antibodies were used as a control. After washing twice, 
secondary antibodies were added where indicated for 20 min at 4°C. After washing, cells 
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were taken up in 200 μl Fixation Buffer (eBioscience). For intracellular staining, cells were 
washed twice, fixed and permeabilized using Fix/Perm solution (eBioscience) for 30 min at 
room temperature. After washing twice, cells were resuspended in 1x Permeabilization 
Buffer (eBioscience) containing antibodies for 40 min at room temperature. All samples 
washed twice before acquisition.
For analysis of pSTAT3 levels, digests were thawed and cultured overnight. The next day, 
digests were incubated for 15 min at 37°C in the presence or absence of 20 IU IL-10 
(Peprotech). After washing, cells were fixed with 100 μl Fixation buffer (eBioscience) for 15 
min at 37°C. After washing, cells were resuspended while vortexing by dropwise addition of 
-20°C pre-chilled True-Phos™ Perm buffer (Biolegend) and incubated for 1 hr at -20°C. 
After washing, antibody staining was performed as described above.
Acquisition of samples was carried out on a BD LSR Fortessa Cell analyzer (BD 
Bioscience). Data were collected using the BD FACS Diva Software version 7 and further 
analyzed with FlowJo v10.0.6 (Tree Star Inc.), and GraphPad Prism v6.0e (GraphPad 
Software Inc.). Data were gated on live cells (Zombie UV negative) and single cells. The 
gating strategy for PD-1 subsets is shown in detail in Fig. 1.
T cell sorting and in vitro expansion of CD8+ T cells
For isolation of indicated cell subsets, cells were thawed, washed and resuspended in 300 μl 
staining buffer containing antibodies. After 20 min incubation at 4°C, cells were washed 
twice and cell sorting was performed using a BD FACS Aria III. Cells were gated on live (PI 
negative), single cells, CD45+, CD3+, bulk (CD14, CD19, CD56, CD4) negative and CD8+ 
cells, and on the population of interest. The detailed gating strategy used to sort intratumoral 
lymphocyte subsets based on PD-1 expression is shown in Supplementary Fig. 3. App. 
3x104 cells were directly sorted in lysis buffer (Arcturus Pico Pure RNA Isolation Kit) and 
used for RNA sequencing. The remainder of the cells were cultured in vitro for further 
experiments.
From eight tumor samples, 5 x 103 T cells PD-1T, PD-1N, and PD-1- T cells were expanded 
in vitro using an excess of irradiated allogeneic feeder cells (4,000 rad) pooled from three 
donors in T cell medium (1:1 mix of AIMV medium (Thermo Fisher) and RPMI 1640 
medium (Sigma), 5% human serum (mix of 3 donors, Blutspendezentrum Basel), 100 units 
penicillin (Sigma), 100 μg/ml streptomycin (Sigma), 2 mM L-glutamine (Sigma), 25 mM 
HEPES (Sigma)) supplemented with 3,000 IU of IL-2 (Peprotech) and 30 ng/ml anti-CD3 
(OKT3, Biolegend)24. Where indicated, cells were expanded with the same protocol 
containing 100 IU IL-2 and 200 IU IL-10 (Peprotech). After day 5, half of the medium was 
replaced with fresh medium containing IL-2 every two to three days. Cells were split 1:2 at 
day 7 or when necessary. At day 15, T cells were tested for PD-1 expression and IFN-γ 
release or cryopreserved until further analysis. Phenotype and effector functions were 
consistent between replicate expansions of the same subsets.
Polyclonal stimulation and assessment of target cell recognition
Cryopreserved tumor digests were thawed, washed and cultured at 3 x 105 cells in 96-well 
plates in tumor medium (DMEM (Sigma), 10% fetal bovine serum (Pan Biotech), 1 mM 
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sodium pyruvate (Sigma), 1x MEM non-essential AA (Sigma), 2 mM L-glutamine, 100 
ng/ml penicillin/streptomycin, 50 nM 2-mercaptoethanol (Sigma), 1 mg/ml ciproxin 
(Bayer)). Cells were stimulated with a suboptimal concentration of 0.5 μg/ml plate bound 
anti-CD3 (OKT3) and 2 μg/ml soluble anti-CD28 (28.2, eBioscience) for 24 or 48 hrs, as 
potent co-stimulatory signals may mask some functional defects of T cells14,50. 20 ng/ml 
IL-10 was added where indicated. Following incubation, supernatants were collected for 
cytokine/chemokine analysis as indicated. Secretion of indicated cytokines and chemokines 
was detected using the LEGENDplex™ Human Th Cytokine and Human Proinflammatory 
Chemokine Panels (Biolegend) as well as the ProcartaPlex Simplex Kits (Invitrogen). For 
intracellular cytokine staining 1x monensin (eBioscience) was added for the last 5 hrs of 
culture and cells were analyzed by flow cytometry.
Sorted PD-1 subsets were rested overnight in complete medium (RPMI, 10% human serum, 
1 mM sodium pyruvate, 1x MEM non-essential AA, 2 mM L-glutamine, 100 ng/ml 
penicillin/streptomycin, 1 mg/ml ciproxin). 3x104 cells were stimulated with anti-CD3/anti-
CD28 for 48 hrs as described above, and supernatants were collected for cytokine/
chemokine analysis.
For investigation of tumor reactivity cryopreserved expanded PD-1 subsets were thawed, 
washed and rested for 24 hrs in 50 IU IL-2. Cells were washed to remove cytokines and 
fluorescently labeled with 1 μM carboxyfluorescein succinimidyl ester (CFSE, Life 
Technologies). Autologous tumor digests were thawed, washed and resuspended in complete 
medium. Percentage of tumor cells in the digests was previously estimated by flow 
cytometry by gating on CD45 negative, FSc high cells. 1 x 105 CFSE-labeled T cells were 
co-cultured with autologous digest at an effector : target cell ratio of 1 : 1. A condition with 
anti-HLA class I blocking antibody (w6/32, Invivo Gen) was included to determine HLA 
class I restriction of the observed reactivity. T cells cultured alone or stimulated with plate 
bound anti-CD3/anti-CD28 or 50 ng/ml PMA/ 1 μg/ml ionomycin (BD) were used as further 
controls. After one hour, 1x monensin and 1x brefeldin A (eBioscience) were added for 
intracellular cytokine staining and cells were incubated overnight before analysis of IFN-γ 
production by flow cytometry.
Immunometabolism
As no difference in metabolism between fresh and frozen T cells was observed, frozen 
samples were used for all these experiments. Cryopreserved tumor digests were thawed, 
washed and rested overnight in tumor medium. The next day, cells were washed and 
incubated at 2 x 105 cells in pre-warmed complete medium containing either 20 μM 2-
NBDG (Thermo Fisher), 100 nM Mitotracker Green FM (Thermo Fisher), 100 nM 
Mitotracker Red CMXRos (Thermo Fisher) or 1 μM Bodipy 500 (Thermo Fisher) for 20 min 
at 37°C in 96-well round bottom plates. Cells were washed and stained with antibodies 
against cell surface antigens as described above. For analysis of lipid content 1 μg/ml 
Bodipy 493 (Thermo Fisher) was added in 1x Permeabilization Buffer for 1 hr at 4°C. Cells 
were analyzed on a BD LSR Fortessa Cell analyzer and metabolic parameters were 
quantified as mean fluorescence intensity. Unstained and single stained cells were used as 
controls.
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Electron microscopy
Sorted cells were fixed with 2.5% glutaraldehyde diluted in 0.1M of phosphate buffer 
solution (PB buffer, Sigma) for 1 hour at room temperature. Cells were spun down and the 
second fixation step was performed for 1 hour at RT with osmium tetroxide (1%), 
glutaraldehyde (2.5%) and potassium ferrocyanide 1.5% diluted in 0.1M PB buffer. Cells 
were washed four times with water and followed by dehydration steps with acetone: 
30%-10min, 70%-10min, and 100% 3x10min. Subsequently, the pellet was incubated in 
Epon resin (100%) overnight at RT and then polymerized in resin at 60°C for 2 days. 50nm 
thin sections were stained with 4% uranyl acetate, followed by Reynolds lead citrate. Images 
were taken at 80kV with a CM100 and TVIPS F416 camera. Cells were randomly chosen on 
the section and 6 images at 4800x magnification + 15 images at 11000x magnification were 
taken.
Chemotaxis
Chemotaxis assays were carried out as described previously45,51, using 96-well transwell 
plates with 5 μm pores (Corning). CXCR5+ CD8+, CD4+ T cells and CD19+ B lymphocytes 
as well as CXCR5- CD3+ T cells were sorted from patient PBMCs and rested overnight in 
complete medium. 2.5 x 104 cells were seeded onto upper wells in 100 μl medium. The 
bottom wells contained 235 μl PBS with or without 1 μg/ml recombinant human CXCL13 
(R&D). After 3 hrs, 50 μl Precision Count Beads™ (Biolegend) were added and 
transmigrated cells were counted by flow cytometry. Cell numbers were calculated using the 
following formula: absolute cell count = cell count / bead count x total bead concentration. 
The chemotactic index was calculated as the ratio of transmigrated CXCR5+ cells over 
transmigrated CXCR5- control T cells.
RNA sequencing, molecular signatures and TCR analysis
High molecular weight RNA (> 200 bp) was extracted from 2,000–40,000 cells collected in 
XB buffer (Life Technologies) using the Arcturus Pico Pure RNA Isolation Kit (Life 
Technologies). Residual genomic DNA was removed using the RNase free DNase set 
(Qiagen). RNA quality and quantity were determined by capillary electrophoresis on 
Eukaryote Total RNA pico chips (Agilent Technologies). High quality RNA (RIN> 7) was 
obtained for all samples.
To prepare and amplify cDNA from 500 pg of total RNA, the SMART-Seq v4 Ultra Low 
Input RNA Kit (Clontech) was used according to manufacturer’s instructions. Amplified 
cDNA was quality controlled by capillary electrophoresis on a Bioanalyzer using High 
Sensitivity chips (Agilent Technologies). Then, 150 pg of amplified cDNA was used for 
Nextera XT library preparation (Illumina) according to manufacturer’s instructions. 
Sequencing libraries were quantified with the Kapa Library Quantification kit (Kapa 
Biosystems) and quality control was performed by capillary electrophoresis on a 
Bioanalyzer using High Sensitivity chips (Agilent Technologies). Libraries were sequenced 
on a HiSeq4000 sequencer (Illumina) for 2 x 50 cycles using HiSeq 3000/4000 PE cluster 
generation kits and HiSeq 3000/4000 SBS Kit sequencing reagents (Illumina).
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All samples were processed as follows: First, reads were mapped against the human genome 
(hg19) using GSNAP [ID: 27008021]. Second, mapped reads were assigned to human genes 
based on GRCh37.75 annotation. Gene expression levels were computed as Reads Per 
Kilobase of transcript per Million mapped reads (RPKM) values as described by Mortazavi 
et al.52 using in-house tools. The LME model framework was used to assess differential 
expression for each gene using log2 RPKM values. The individual donor was treated as a 
random effect and the three PD-1 subgroups were used as fixed effects. Significantly 
regulated genes were reported at Benjamini–Hochberg [https://www.jstor.org/stable/
2346101] FDR<0.01 and an absolute log2 fold-change ≥ 1. In total, 997 annotated genes 
were detected. Principal component analysis was performed on mean centered data using in-
house R scripts. Hierarchical clustering was performed on the set of significantly regulated 
genes using complete-linkage and Euclidean distance. Sub-clusters were derived using the R 
function cutree53. The Hypergeometric test was conducted to identify enriched biological 
processes annotated by gene ontology (GO) terms for each sub-cluster using the 
‘GOHyperGParams’ method from the R package GOstats [ID: 17098774]. P-values were 
corrected using Benjamini-Hochberg method. All biological processes with the adjusted P 
value less than 0.05 were considered as significantly enriched. Gene set enrichment analysis 
(GSEA, http://broadinstitute.org/gsea) was used to determine whether predefined exhaustion 
gene sets showed enrichment in the PD-1T and PD-1N subsets (Crawford et al., 2014; 
Schietinger et al., 2016, Gupta et al., 2015, Quigley et al., 2010, Zheng et al., 2017, Doering 
et al., 2012, Baitsch et al., 2011, Tirosh et al., 2016, Singer et al., 2016). T cell receptor beta 
chain clonality was assessed using the MiXCR tool using standard parameters of the 
RNAseq workflow. TCR clonality was analyzed using the R package tcR [ID: 26017500]54. 
RNA sequencing data are available at NCBI GEO: (GSE99531).
Immunohistochemistry and digital image analysis
Strict serial sections 4 μm were cut from formalin-fixed paraffin embedded tissue blocks of 
primary NSCLC. Deparaffinization was performed according to standard protocols. Sections 
were pre-treated and stained with monoclonal antibodies directed against CD4 (4B12, 
Novocastra), CD19 (LE-CD19, Dako), CD21 (1F8, Dako), Bcl-6 (PG-B6p, Dako) on a 
Leica-Bond™ III/max autostainer platform (Leica Biosystems). Stains were detected using 
anti-Ig coupled horseradish peroxidase with 3,3’-diaminobenzidine (DAB) as substrate. 
Nuclear counterstaining was performed with Mayer hematoxylin. Immunohistochemical 
single staining for PD-1 was carried out using a Roche Benchmark Ultra (NAT105, Roche 
Diagnostics, Ventana/DAB detection). Immunohistochemical double stains for CD8 and 
PD-1 were performed using the PD-1 staining protocol on a Roche Benchmark Ultra 
followed by CD8 staining (4B11, Refine Red detection) on a Leica-Bond™ III/max 
autostainer.
Slides were scanned at high resolution on a CD-IVD certified Philips Ultra Fast Scanner 300 
(Philips Digital Pathology Solutions) and digital image analysis was carried out by an 
experienced pathologist (VHK) using the HALO™ image analysis software, v.2.0.1145.19 
(Indica Labs). Classification of PD-1T, PD-1N and PD-1- cells on single stains was 
performed using computationally derived cutoffs, which were identified by comparing FFPE 
samples with flow cytometry guided annotation of the PD-1 subsets in matched samples. For 
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assessment of double stains, marker recognition and color deconvolution was tested and 
optimized on CD8/PD-1 double positive cells. For TLS assessment, digital slides were 
reviewed and tertiary lymphoid structures (TLS) were manually annotated.
Statistical analysis
Data are reported as the mean ± SD or mean ± SEM, as specified. Statistical significance 
was determined using one-way or two-way ANOVA or Mann-Whitney test as indicated 
(Prism version 7, GraphPad Software). Differences were considered statistically significant 
if *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Only significant p-values are displayed. 
Unless otherwise specified, experiments were performed without duplicate due to material 
restrictions. Functional data are representative of at least three experiments.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Co-receptor expression, functionality and tumor reactivity of CD8+ PD-1+ TIL 
populations in NSCLC.
(a) Gating strategy of CD8+ TIL subsets according to PD-1 MFI for subgroup analysis, one 
exemplary NSCLC specimen is depicted. (b) Co-expression of other immune checkpoints on 
PD-1 subgroups in NSCLC specimens (n=24). Lines and boxes represent mean and SD, 
respectively. (c) Gating strategy to identify PD-1 subsets within peripheral blood CD8+ T 
cells of healthy donors and within intratumoral T cells in NSCLC. (d) Effector cytokine 
secretion of sorted PD-1 subsets with and without anti-CD3/anti-CD28 stimulation 
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measured by bead-based immunoassay (mean and SEM of three donors). (e) Clonality of the 
TCR repertoire of PD-1T, PD-1N and PD-1- TILs. Data from 11 NSCLC specimens are 
shown as box-and whisker-plots (the lines indicate median values, the boxes interquartile 
range (IQR) values and the whiskers 1.5IQR values as calculated by Tukey) (left). ***P < 
0.001 by one-way analysis of variance (ANOVA). The average relative abundance of the 
most frequent TCRβ clonotype, the second most frequent, the 3rd to 30th most frequent, and 
the remaining clonotypes are shown for all 11 donors (right). (f) Frequency of the 30 most 
abundant TCR sequences of the PD-1T subset within PD-1T, PD-1N and PD-1- populations. 
Shown are the mean percentage and standard deviation of all 11 donors. ***P < 0.001, 
****P < 0.0001 by one-way ANOVA. (g) Expression of CD137 in PD-1 subgroups (n=24). 
Lines and boxes represent mean and SD, respectively. (h) Flow cytometry plot and 
quantification of pre-/postexpansion PD-1 expression and IFN-γ secretion of TILs expanded 
from the three sorted PD-1 subsets (n=3 NSCLC specimens). PD-1 MFI was analyzed 
within CD3+CD8+ cells from each expanded subset. Bar graphs indicate mean and SEM. 
***P < 0.001 by two-way ANOVA. (i) IFN-γ expression of expanded PD-1T, PD-1N and 
PD-1- TILs from the eight donors upon co-culture with autologous digests. The difference 
with and without HLA class I blocking antibody is depicted for each individual donor (left) 
and T cell only and PMA/ionomycin controls are shown for all samples (mean and SD, 
right).
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Figure 2. Gene expression profile of sorted PD-1T, PD-1N and PD-1- TILs from NSCLC 
specimens.
(a) Principal component analysis (left) and bar plots for the means of the PC1 and PC2 
values (right) for sorted PD-1T, PD-1N, PD-1- TILs (n=11) and healthy donor effector 
memory (EM) T cells (n=4). Error bars represent the SEM. *P < 0.05, **P < 0.01, ***P < 
0.001, ****P < 0.0001. (b) Significantly regulated genes between the three PD-1 subsets. 
Significance was determined as Benjamini-Hochberg FDR<0.01 and log2 fold change ≥1. 
(c) Clustering analysis for genes distinguishing PD-1T from PD-1N and PD-1- subsets. (d) 
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Selected clusters showing up- or downregulation of key biological processes (Gene ontology 
(GO) terms). (e) Biological processes (GO terms) enriched in clusters 5 and 7. Numbers in 
parentheses indicate the number of genes within each GO term. (f) Increased expression of 
the proliferation marker Ki67 (MKI67) at the mRNA level (left, n=11), and at the protein 
level as assessed by intracellular staining of ex vivo tumor digests (n=5, middle) and sorted 
PD-1 subsets that were cultured for 48 hrs (n=3, right). The lines in the box-and whisker-
plot indicate median values, the boxes IQR values and the whiskers 1.5IQR values as 
calculated by Tukey. The dot plots and bar graphs represent mean and SEM. *P < 0.05, ***P 
< 0.001, ****P < 0.0001 in (b), (c) and (d) by one-way ANOVA.
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Figure 3. PD-1T TILs show overexpression of inhibitory receptors, but display a key gene 
signature distinct from exhausted T cells in murine chronic infection and cancer.
(a) Volcano plot of up- or downregulated genes between PD-1T and PD-1N TILs, with a set 
of genes encoding inhibitory receptors and molecules involved in proliferation and 
differentiation annotated (n=11 tumor specimens). Significance was determined as 
Benjamini-Hochberg FDR<0.01 and log2 fold change ≥1. (b) Surface expression of 
indicated receptors on PD-1T, PD-1N, and PD-1- gated TILs in tumor digests (n=8), as 
determined by flow cytometry. (c) Expression of the ‘exhaustion genes’ described in Zheng 
et al.27 in the indicated PD-1 subsets (n=11). The lines in the box-and whisker-plots indicate 
median values, the boxes IQR values and the whiskers 1.5IQR values as calculated by 
Tukey. (d) Surface expression of CD27 and KLRG1 on PD-1T, PD-1N, and PD-1- gated 
TILs in tumor digests (n=8), as determined by flow cytometry. Each dot represents one 
patient. Bar graphs indicate mean and SEM. **P < 0.01, ***P < 0.001, ****P < 0.0001 in 
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(b), (c) and (d) by one-way ANOVA. (e) Venn diagram comparing the overlap of the 
differentially expressed genes between PD-1T and PD-1N TILs with the genes derived from 
the chronic LCMV and the early/late-stage tumor signatures, respectively. (f+g) Gene set 
enrichment analysis (GSEA) of published data sets from exhausted T cells in (f) chronic 
murine LCMV infection (Crawford et al.) and (g) murine tumors (Schietinger et al.) within 
the gene signatures derived from the differently expressed genes between PD-1T and EM T 
cells or PD-1N and EM T cells (n=11 tumor specimens and 4 healthy donors). Statistical 
significance was determined by permutation testing with NES (normalized enrichment 
score).
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Figure 4. Alterations in glucose, lipid and mitochondrial metabolism in PD-1T TILs.
(a) Representative histograms of metabolic parameters analyzed by flow cytometry in T 
cells of one donor (from n=3 independent experiments). (b) Glucose uptake (2-NBDG), (c) 
lipid content (Bodipy 493), uptake (Bodipy 500) and CD36 expression, and (d) 
mitochondrial mass (indicated by MTG), membrane potential ΔΨm (MTR), and normalized 
ΔΨm (MTR/MTG ratio) of PD-1T, PD-1N and PD-1- gated TILs in 11 tumor digests. Shown 
are mean and SD. *P < 0.05, ****P < 0.0001 in (b), (c) and (d) by one-way ANOVA. (e) 
Representative electron micrographs of sorted PD-1T and PD-1N T cells and their randomly 
selected mitochondrial ultrastructures. Analysis of PD-1- T cells or of independent 
biological replicates was precluded by limited cell numbers. Scale bars, 500 nm. 
Quantification of mitochondria numbers per cell, numbers of cristae in mitochondria and 
total cristae length normalized to the surface area of mitochondria using Image J. Sample 
identity was blinded to the analyser and at least 10 randomly selected TILs in each group 
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were quantified (PD-1T: 10, 27, and 21 TILs; PD-1N: 15, 23, and 12 TILs for each separate 
analysis). Data represent mean ± SD. *P < 0.05, ***P < 0.001 by Mann-Whitney test.
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Figure 5. PD-1T TILs display a fixed state of dysfunction.
(a) Expression of Tim-3 and Lag-3 in IL-2 expanded sorted TILs (n=3). Shown are mean 
and SEM. (b) IL-10 expression by indicated cell subsets in tumor digests and correlation of 
IL-10 expressing cells with the number of PD-1T TILs (n=8). Lines in box-and-whisker-
plots indicate median values, boxes indicate IQR values and whiskers minimum and 
maximum values. R2 = 0.61 was calculated using linear regression analysis. (c) PD-1 
upregulation in sorted TIL subsets after withdrawal of IL-2 and short-time IL-10 exposure 
(n=3). Bar graphs indicate mean and SEM. *P < 0.05, **P < 0.01 by one-way ANOVA. (d) 
IFN-γ production of IL-10 expanded PD-1T, PD-1N, PD-1- sorted TILs (n=3). Bar graphs 
indicate mean and SEM. (e) IL10R and perforin expression in IL-2 expanded TIL subsets 
with and without IL-10 stimulation.
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Figure 6. CXCL13 expression of PD-1T TILs and predictive potential for response to PD-1 
blockade.
(a) Expression of indicated inflammatory cytokines and chemokines in sorted PD-1T TILs 
after 24 hrs of resting by bead-based immunoarray. Shown are mean and SEM of 3 donors. 
(b) Migration of peripheral blood CXCR5+ CD8+, CD4+ and CD19+ and CXCR5- CD3+ 
immune cell subsets in response to CXCL13. Shown are the mean and SEM from three 
donors. (c) Digital markup images showing the color deconvolution of 
immunohistochemistry staining of CD8 (red) /PD-1 (brown) double positive cells. (d) 
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Immunohistochemical analysis of tertiary lymphoid structures (TLS) in lung cancer. 
Distribution of TLS in the tumor (large image, arrows indicate TLS, H&E). TLS show 
accumulation of CD8/PD-1T double positive and CD4+ T cells in the periphery of the 
follicular structure. Interspersed Bcl6+ cells likely represent follicular helper T cells. A well-
formed CD21+ follicular dendritic cell network with strong accumulation of B cells is found 
in the center of the follicle. Digital markup image showing the color coding of CD8+ (red), 
PD-1+ (green), CD8+PD-1+ (yellow) and double negative (blue) cells in the TLS. (e) Digital 
markup images showing the localization of CD8+, PD-1+ and CD8+PD-1+ cells in five 
different NSCLC specimens. (f) Quantification of PD-1T TILs localized within and outside 
of TLS in NSCLC specimens by digital image analysis (n=10). Shown are mean and SD. 
**P < 0.01 by Mann-Whitney test. (g) Percentage of PD-1T TILs per total cells or number of 
PD-1T cells per mm2 in responders (n=7) and non-responders (n=14) to PD-1 blockade. 
Shown are mean and SD. ****P < 0.0001 by Mann-Whitney test. (h) Overall survival of 
patients with tumors harboring more or less than 1% of PD-1T cells (n=21). P value was 
determined by log-rank test. (i) Duration of response in the seven responding patients.
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